Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-week Multicenter Study from the Porto Group of ESPGHAN

Key Points

• Maintenance therapy with upadacitinib significantly improved clinical outcomes in pediatric ulcerative colitis patients.
• After 52 weeks, 70% of participants achieved remission, indicating a strong treatment response.
• Multicenter study design ensured diverse patient representation, enhancing the reliability of the findings.
• The results suggest the need for further evaluation of long-term benefits and safety in this young demographic.